Silence Therapeutics PLC Sponsored ADR
Silence Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $559,000.00, down 98.7% from fiscal 2024. In the quarter to June 2026, revenue grew 197.2%, EPS grew 54.4% and free cash flow grew 107.0%, each against the same quarter a year earlier.
Follow SLN
Silence Therapeutics PLC Sponsored ADR (SLN) Beneish M-score
Silence Therapeutics PLC Sponsored ADR's Beneish M-score for fiscal 2025 is 45.78; values above −1.78 are the model's flag for possible earnings manipulation — a statistical screen, not a finding.
Beneish M-score, annual
Embed this chart
Annual newest first
| Period | Beneish M-score | Change (points) |
|---|---|---|
| FY2025 | 45.78 | 47.64 |
| FY2024 | −1.86 | 0.53 |
| FY2023 | −2.39 | (0.84) |
| FY2022 | −1.55 | 2.61 |
| FY2021 | −4.17 | — |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Days’ sales in receivables index | 67.13 | — | 61.76 | |
| Gross margin index | 1.18 | — | 0.62 | |
| Asset quality index | 1.28 | — | 0.52 | |
| Sales growth index | 0.01 | — | 0.01 | |
| Depreciation index | 0.95 | — | 0.11 | |
| SG&A index | 64.32 | — | −11.06 | |
| Total accruals to total assets | (0.20) | — | −0.94 | |
| Leverage index | 1.25 | — | −0.41 | |
| Beneish M-score | Flagged by the model | 45.78 | ||
How the Beneish M-score works
M = −4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI (Beneish, 1999): eight changes in the accounts from one fiscal year to the next, which the model weighs for the pattern seen in companies that later restated their earnings. Higher is worse.
| below −2.22 | Low — no pattern the model associates with manipulation |
|---|---|
| −2.22 to −1.78 | Elevated |
| above −1.78 | Flagged by the model |
−1.78 is the cut-off usually quoted from the paper, −2.22 a common conservative one. A statistical screen, not a finding of wrongdoing.
When asset quality, depreciation or SG&A cannot be worked out, that index is set to 1, as Beneish did, and the breakdown says so; with all three missing there is no score. Depreciation includes amortisation, and asset quality leaves out securities. Not worked out for banks, insurers and REITs.
Beneish M-score against peers
| Company | Beneish M-score |
|---|---|
| VALN Valneva SE Sponsored ADR compare | −3.3× |
| PHAT Phathom Pharmaceuticals, Inc. compare | −1.4× |
| ZVRA Zevra Therapeutics, Inc. compare | 1.5× |
| CRMD CorMedix Inc compare | 12.8× |
| SLN Silence Therapeutics PLC Sponsored ADR | 45.8× |
| OLMA Olema Pharmaceuticals, Inc. compare | — |
| STTK Shattuck Labs, Inc. compare | — |
| DBVT DBV Technologies S.A. compare | — |
| SGMT Sagimet Biosciences Inc. compare | — |
What Beneish M-score is
The Beneish M-Score combines eight year-on-year changes in the accounts into a statistical screen for patterns seen in companies that overstated earnings.
−4.84 + 0.920 × DSRI + 0.528 × GMI + 0.404 × AQI + 0.892 × SGI + 0.115 × DEPI − 0.172 × SGAI + 4.679 × TATA − 0.327 × LVGI